ADVANCED TECHNOLOGIES FOR SCALABLE AAV VECTOR PRODUCTION
Free Online Seminar by Dr. Nicole Faust, CEO. Learn about the latest developments in using stable producer cell lines for AAV manufacturing and how the ELEVECTA® system enables a fully scalable and robust vector production process without plasmid transfection or helper viruses.
Cell & Gene Therapy Manufacturing & Commercialization Digital Week – May 3, 2022
CEVEC PHARMACEUTICALS CEO STRESSES CHALLENGES IN PRODUCING AAV VECTORS
Interview with Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals at the Cell & Gene Meeting on the Med in Barcelona, Spain.
The Science Advisory Board – April 26, 2022
GENE THERAPY ON THE VERGE OF TAKING ITS NEXT EVOLUTIONARY STEP
Interview by Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals
Pharm Exec.com, Brand Insights Contributor – April 22, 2022
MANUFACTURING OF RCA-FREE ADENOVIRAL VECTORS
Free Online Seminar by Dr. Nico Scheer, Senior Consultant, Business Development, CEVEC Pharmaceuticals / Professor “Molecular Biology“, FH Aachen University of Applied Sciences
Cell & Gene Therapy Insights – February 22, 2022
Complimentary live 30 poster
MANUFACTURING OF RCA-FREE ADENOVIRAL VECTOR VACCINES
Sponsored article by CEVEC authors Silke Wissing, Helmut Kewes and Nico Scheer
Genetic Engineering & Biotechnology News (GEN) – December 3, 2021
TRANSFER AND SCALE-UP FROM 10 L BIOBLU®️ TO ALLEGRO™ STR 50 AND STR 200 BIOREACTORS
In this article, David Mainwaring et al. discuss Pall and CEVEC’s recent collaboration to demonstrate scalability of a transient transfection-free, stable AAV producer cell line from the bench-scale 10L production bioreactors to the Pall Allegro™ STR 50L and STR 200L bioreactors.
Cell & Gene Therapy, Bio Insights – November 25, 2021
CAP®AD – A VERSATILE PLATFORM FOR RCA-FREE, INDUSTRIAL SCALE ADENOVIRAL VECTOR PRODUCTION
White Paper by CEVEC authors Silke Wissing, Helmut Kewes and Nico Scheer
Bioprocess International Magazine, Multimedia Placement, October 2021
MANUFACTURING ADENOVIRAL VECTORS AT LARGE SCALE
How to select the best process and cell line to avoid RCA formation
Sponsored article by CEVEC authors Silke Wissing, Nicole Faust and Nico Scheer, Page 35
Genetic Engineering & Biotechnology News (GEN) – 40th Anniversary Edition, October 2021
HIGH TITER rAAV PRODUCTION IN BIOREACTOR USING ELEVECTA® STABLE PRODUCER CELL LINES
Scientific Poster, J. Coronel, A. Al-Dali, A. Patil, K. Srinivasan, T. Braß, K. Hein, S. Wissing
ESGCT 2021, October 2021
DEVELOPMENT OF A HEK293-BASED FULLY STABLE,
HELPER VIRUS-FREE ELEVECTA PRODUCTION SYSTEM FOR rAAV
Scientific Poster, B Hudjetz, S Schmidt-Hertel, T Grabeck, K Srinivasan, A Al-Dali, J Coronel, N Strempel, N Faust, S Wissing
ESGCT 2021, October 2021
AAV MANUFACTURING WITH STABLE PRODUCER CELLS FOR INDUSTRIAL SCALE VECTOR PRODUCTION
Free Online Seminar, Dr. Ben Hudjetz, Senior Scientist Cell Line Development, CEVEC
Cell & Gene Therapy, Bio Insights – September 16, 2021
GENTHERAPIEN MIT AAV-VEKTOREN
CEVEC Pharmaceuticals: Hochleistungszelltechnologien für Biotherapeutika
Interview mit Dr. Nicole Faust, CEO, CEVEC
Plattform Life Science – September 2021
ELEVECTA® – THE FUTURE OF AAV GENE THERAPY VECTOR PRODUCTION
Pharmaceutical companies with gene therapies in their pipeline need to establish scalable production processes that can keep up with the increasing demand in terms of volume, quality and robustness, says CEVEC.
BPI Contributor – November 3, 2020
HOW TO SOLVE THE PRODUCTION CHALLENGES OF AAVS FOR GENE THERAPY
CEVEC Pharmaceuticals has found a solution and developed a platform that can produce adeno-associated viral vectors (AAVs) as easily as if they were monoclonal antibodies.
Labiotech.eu – June 3, 2020
Read the interview with Nicole Faust, CEO of CEVEC
CEVEC PHARMACEUTICALS GMBH HAS LAUNCHED A NEW, SCALABLE PRODUCTION PLATFORM FOR AAV GENE THERAPY VECTORS.
At the time of Cevec Pharmaceuticals’s announcement, US researchers reported that AAV gene therapy might be the most promising way to bridge the therapeutic gap until a COVID-19 vaccine is available.
European Biotechnology – April 29, 2020